The page lists rodent and cell-culture studies, tissue preparation, cytotoxicity and neuroprotection assessments, oxidative stress and neuroinflammation measurements, and analyses of dopaminergic neurons and alpha-synucleinopathy.
NeuroSoV is a biotech company focused on discovering and developing therapies intended to slow neurological disorders. Its first asset targets Parkinson disease and aims to slow and treat the disease.
Parkinson’s disease affects more than 10 million people globally and carries an economic and societal burden. Current treatments manage symptoms but do not cure the disease or delay its progression.
A company based in Covilhã is finalizing pre-clinical tests on an enzyme responsible for producing oxidative stress. It hopes to license a drug intended to prevent Parkinson’s progression, with the reported work focused on the enzyme associated with oxidative stress.
